Sinusitis and oroantral fistula in patients with bisphosphonate-associated necrosis of the maxilla
© Voss et al. 2016
Received: 17 June 2015
Accepted: 28 December 2015
Published: 6 January 2016
The management of bisphosphonate related necrosis of the jaw has become clinical routine. While approximately two thirds of the lesions are in the mandible, one third is located in the maxilla. In 40–50 % of maxillary necrosis the maxillary sinus is involved, leading to maxillary sinusitis and oro-antral communications.
This retrospective single center study includes all patients with diagnosis of BP-ONJ of the maxilla and concomitant maxillary sinusitis. The information collected includes age, gender, primary disease, bisphosphonate intake, involving type of bisphosphonate, route of administration and duration of BP treatment previous to surgical treatment and treatment outcome.
A total of 12 patients fulfill the criteria of the diagnosis of maxillary sinusitis associated to maxillary necrosis, of which 6 Patients showed purulent sinusitis. All patients underwent surgical treatment with complete resection of the affected bone and a multilayer wound closure. A recurrence appeared in one patient with open bone and no sign of sinusitis and was treated conservatively.
Purulent maxillary Sinusitis is a common complication of bisphosphonate-related necrosis of the maxilla. The surgical technique described can be suggested for the treatment of these patients.
KeywordsNose and paranasal sinuses Medication-associated necrosis of the jaws Zoledronate Purulent sinusitis
Since its first description in 2003, reports of bisphosphonate related osteonecrosis of the jaw (BP-ONJ) accumulate. With the ability to reduce bone turnover through selective inhibition of osteoclasts, Bisphosphonates are used widespread in treatment of osteoporosis and bony metastases of malignant diseases. They are administered orally or intravenously, whereat the bioavailability of oral bisphosphonates is below 1 % . Once circulating in the blood, 70 % are covalently bound to hydroxyapatite in bony tissues, the remainder is secreted via the kidneys. BPs bound to the bone are biologically inert, however, when absorbed by osteoclasts they lead to concentration dependent apoptosis via inhibition of Farnesyl-Pyrophosphate-synthase . Being integrated only during bone turnover, concentration is suspected to be higher in areas of high turnover such as the alveolar processes . Due to local factors like chewing forces, oral bacteria, the periodontal gap and a thin mucosa, the alveolar bone necessitates an elevated osteoclast-dependent bone turnover to maintain integrity . When osteoclasts are diminished by a high local concentration of BPs, the bone is not capable to react to these local factors what may end in necrosis . The prominent role of osteoclast inhibition in the pathogenesis of BP-ONJ is underlined by recent reports of osteonecrosis of the jaw following the treatment with Denosumab, a selective antibody against RANK-L and thus potent inhibitor of osteoclasts and its precursors, which have a similar incidence like BP-ONJ after the treatment with Zoledronate (ZOL), the BP with the highest antiresorptive potency .
The incidence of BP-ONJ is dependent on bisphosphonate type, route of administration and cumulative dose, underlying disease, gender, co-medication and oral health. It is lowest for oral treatment of primary osteoporosis (0.05-0.2 %) and highest for intravenous treatment of malignant diseases with bone metastases, intravenous administration of ZOL and additional treatment with inhibitors of angiogenesis or tyrosine-kinase (up to 20.5 %) .
Treatment suggestions of BP-ONJ differ. In the 2014 update on Medication related osteonecrosis of the jaws the American Association of Oral and Maxillofacial Surgeons (AAOMS) recommends surgical debridement or resection only in stage 2 and 3. Their approach has the major treatment goals to enable continued oncological therapy and preserve quality of life . However, the favored treatment with antibacterial mouth rinse and antibiotic therapy only leads to freedom of symptoms in 53 % of the patients . After promising results of a surgical approach, that can lead to a closed oral mucosa and absence of inflammation signs in 80-100 % of the cases, other national associations favor a complete necrosectomy with primary wound closure when the patients general condition allows it .
Roughly two thirds of the lesions occur in the mandible, only one third arises in the maxilla. While a plethora of articles present different perspectives of BP-ONJ, only few studies explicitly highlight the manifestation in the maxilla and only a case series of three patients exists for a defined treatment regime [11–15].
The aim of this study was to review our cases with maxillary BP-ONJ and concomitant sinusitis and to introduce a technique for their management.
This retrospective study includes all the patients with the diagnosis of bisphosphonates-related osteonecrosis of the maxilla and maxillary sinusitis that were operated in our department between 2007 and 2011. Patients without maxillary sinusitis, without a diagnosis consistent with BP-ONJ or with history of radiation therapy to the jaws were excluded. Data was collected using the hospital information system.
Postoperatively, patients were fed via a nasogastric feeding tube for five days. Intravenous antibiotic treatment was continued until discharging the patient after 6 days. Until removal of sutures 18–21 days postoperatively, patients were asked to only eat soft food, avoid blowing their noses and use xylometazoline nasal spray and inhalation with natural brine and chlorhexidine mouthwash frequently.
Postoperative controls were carried out for removal of sutures and then every six months. When recall in our unit was not feasible (e.g. distant place of residence) controls were carried out by the local dentist.
Twelve Patients met the inclusion criteria (10 female, 2 male) with a mean age of 67 years (range 55–82). Mean follow up time was 25 months (range 19 – 58). Mean duration of BP-treatment was 71 months (range 24–144 months), five patients received Zoledronate (mean 50 months, range 36–70), three patients were treated with Pamidronate (mean 117 months, 66–144 months), two with Ibandronate (mean 72 months, 48 and 96) and one with Alendronate (24 months) and Clodronate (84 months) each. Except for Alendronate and Clodronate, the route of administration was intravenously. The underlying diseases were breast cancer and multiple myeloma in five patients, and lung cancer and osteoporosis in one case respectively. BP-ONJ arose after tooth extraction in 6 patients. In 3 patients periodontitis was noted as initiating factor, which could not be clearly defined in the remaining three patients.
Eleven of twelve patients had an uneventful wound healing. One patient had a relapse of open bone 18 months after the surgery. However, the sinus was obstructed with a thick soft tissue scar. It was decided only to remove bony edges and sequestra not to endanger the delineation of the sinus. Two years later the patient showed up with an abscess of the ipsilateral cheek that was incised. Short time later she succumbed to the metastasizing breast cancer.
BP-ONJ is a side effect of antiresorptive treatment with growing importance that arises more frequently in the mandible than in the maxilla. The difference in bone architecture with its reduced blood supply might be an explanation, on the other hand, saliva and food particles accumulate in the mandible and might support local infections. Because of the good vascularization of the maxilla, osteomyelitis is rare in contrast to the mandible, where the thick cortical bone is nutritioned as an endartery system. Due to expansion of the maxillary sinus, the bony volume of the dorsal maxillary alveolar crest is mostly small, just reaching the root apices. Infections of the maxillary bone are likely to affect the maxillary sinus. The maxillary sinus itself is lined with a thin mucosa that early reacts to dental infections . When periodontal infections or dental extractions lead to BP-ONJ of the dorsal maxilla, an involvement of the maxillary sinus is not unlikely: 40–50 % of the patients with a maxillary BP-ONJ show an ipsilateral maxillary sinusitis  and oro-antral fistulas occur in one third of the cases with maxillary BP-ONJ, and their management is demanding .
Triggering factors for BP-ONJ are tooth extractions and other dental surgical procedures, sharp bony edges and pressure marks. Other regions than the jaws are extremely rarely involved in Bisphosphonate-associated osteonecrosis. Some authors mention cutaneous manifestation such as dental sinus tracts , and only few case reports with Bisphosphonate-associated osteonecrosis of the external auditory canal (BPECO) are available . The similarity of thin soft tissue coverage of the bone may explain a pathogenesis by minor self-inflicted trauma by regular aural toilet with cotton buds or fingers in the outer ear. Also secondary osteomyelitis can arise after otitis, mastoiditis or sinusitis and may lead to osteonecrosis.
Remarkably, the sinus mucosa in all patients of the present study was altered. Similarly to the oral mucoperiosteum, which can be very easily detached from the bone in patients treated with BPs, it could be removed from the underlying sinus bone without significant force. This supports the theory that soft tissue adjacent to bone is more affected by BPs than soft tissue that is not in connection with bone . It is discussed that BPs are released from the bone by osteoclasts and low pH-values and then internalized by fibroblasts and epithelial cells . Zoledronate inhibits proliferation and elevates apoptosis of these soft tissue cells, and inhibits expression of type-1-collagen . As the periosteal membrane is connected to the bony surface by collagenous fibers, and type-1-collagen expression needs to be increased in maxillary mucosa healing, inhibition of fibroblasts and epithelial cells might explain the easier detachment of the periost and Schneiderian membrane . Because vascular remodeling and neovascular formation is delayed, soft tissue regeneration may also be impaired in patients with BP-ONJ .
Treatment suggestions of manifest BP-ONJ differ. Whereas the first reports on management of BP-ONJ preferred a conservative approach, recent publications favor a surgical approach. While many authors describe treatment results between 84 and 100 % of mucosal healing after complete necrosectomy and thorough wound closure [16, 25, 26] healing of the necrosis occurs in only 25 % after strictly conservative measures and 28–58 % after partial resections or debridement without soft tissue closure [27, 28]. The more advanced regimes also reflect the argument that in most patients a continued treatment with BPs is necessary. This leads to higher concentrations in the jawbones resulting in even worse healing of bone and soft tissue wounds when surgery is done at a subsequent date. However, in its 2014 update of the position paper the AAOMS still recommends management with antibacterial mouth rinses and antibiotics in most patients . In the experience of our group the conservative treatment of maxillary sinusitis did not lead to healing but to purulent discharge . Persisting oro-antral communications can be covered with obturators, albeit ill-fitting dentures my lead to new osteonecrosis .
The technique proposed is adapted from a report of our group published in 2012 where five of the 21 lesions implicated the maxilla . One of the patients in this current paper with multiple myeloma and Zoledronate treatment was already reported in the previous paper. In contrast to the technique described by Gallego et al. we tried not to use the pedicled buccal fat pad in the first surgical intervention in order to have more options in a possible later operation . While the buccal fat pad provides a mechanic protection and a rich vascularization in the BRONJ site, in the technique used, the periosteum that is quilted under the palatal mucosa serves as a second layer for a reliable wound closure and helps to develop a thick scar that seals off the bone from the oral flora.
Interestingly, one of our patients who had a purulent sinusitis with a 9 × 8 mm measuring sequestrum did not show any exposed bone intra- or extraorally, and tooth extractions in the right maxilla had been carried out more than one year before. In the last years, the non-exposed variant has led to a discussion concerning the staging of BP-ONJ . In most reports however, sites with the absence of a clear mucosal breakdown were declared as non-exposed BP-ONJ even though sinus tracts or periodontitis lesions existed. To our best knowledge a purulent maxillary sinusitis caused by a BP-ONJ sequestrum with completely bland oral mucosa has not been described before. As they may lead to pansinusitis, and orbital or intracranial implication, purulent sinusitis has the potential of life threatening complications and need to be treated early . In our case low dose cone beam CT helped to assess the sequestrum and a complete unilateral opacification of the sinus, and the patient had no remaining symptoms after sequester removal, sinus surgery, and meticulous wound closure.
Maxillary sinusitis and oro-antral communication associated to maxillary osteonecrosis is a severe complication of BP therapy. Cone beam computer tomography and endoscopy are helpful diagnostic and intraoperative tools. In combination with antibiotic treatment, the technique described can be suggested for the management of BP-ONJ and concomitant maxillary sinusitis.
Consent from the local Ethics Committee was obtained prior to the study. All patients gave informed consent to publish clinical photographs. The article processing charge was funded by the German Research Foundation (DFG) and the Albert Ludwigs University Freiburg in the funding programme Open Access Publishing. There was no additional funding for this study.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18:75–85.View ArticlePubMedGoogle Scholar
- Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res. 2007;86:1022–33.View ArticlePubMedGoogle Scholar
- Dixon RB, Tricker ND, Garetto LP. Bone turnover in elderly canine mandible and tibia. J Dent Res. 1997;76:336.Google Scholar
- Shibutani T, Murahashi Y, Tsukada E, Iwayama Y, Heersche JN. Experimentally induced periodontitis in beagle dogs causes rapid increases in osteoclastic resorption of alveolar bone. J Periodontol. 1997;68:385–91.View ArticlePubMedGoogle Scholar
- Cheong S, Sun S, Kang B, Bezouglaia O, Elashoff D, McKenna CE, et al. Bisphosphonate uptake in areas of tooth extraction or periapical disease. J Oral Maxillofac Surg. 2014;72(12):2461–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48:3082–92.View ArticlePubMedGoogle Scholar
- Walter C, Al-Nawas B, Frickhofen N, Gamm H, Beck J, Reinsch L, et al. Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med. 2010;6:11.View ArticlePubMedPubMed CentralGoogle Scholar
- Ruggiero SL, Dodson TB, American Association of Oral and Maxillofacial Surgeons. Position paper on medication-related osteonecrosis of the jaws- 2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–56.View ArticlePubMedGoogle Scholar
- Van den Wyngaert T, Claeys T, Huizing MT, Vermorken JB, Fossion E. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol. 2009;20:331–6.View ArticlePubMedGoogle Scholar
- Grötz KA, Piesold J-U, Kopp I, Follmann M, Berlin DKG, Marron M, et al. Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen. AWMF online. 2012;4:2012.Google Scholar
- Infante-Cossio P, Lopez-Martin JC, Gonzalez-Cardero E, Martinez-de-Fuentes R, Casas-Fernandez-Tejerina A. Osteonecrosis of the maxilla associated with cancer chemotherapy in patients wearing dentures. J Oral Maxillofac Surg. 2012;70:1587–92.View ArticlePubMedGoogle Scholar
- Maurer P, Sandulescu T, Kriwalsky MS, Rashad A, Hollstein S, Stricker I, et al. Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris. Int J Oral Maxillofac Surg. 2011;40:285–91.View ArticlePubMedGoogle Scholar
- Koulocheris P, Weyer N, Liebehenschel N, Otten JE, Gutwald R, Schmelzeisen R. Suppurative maxillary sinusitis in patients with bisphosphonate-associated osteonecrosis of the maxilla: report of 2 cases. J Oral Maxillofac Surg. 2008;66:539–42.View ArticlePubMedGoogle Scholar
- Gallego L, Junquera L, Pelaz A, Hernando J, Megias J. The use of pedicled buccal fat pad combined with sequestrectomy in bisphosphonate-related osteonecrosis of the maxilla. Med Oral Patol Oral Cir Bucal. 2012;17:e236–41.View ArticlePubMedGoogle Scholar
- Mast G, Otto S, Mucke T, Schreyer C, Bissinger O, Kolk A, et al. Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw. J Craniomaxillofac Surg. 2012;40:568–71.View ArticlePubMedGoogle Scholar
- Voss PJ, Joshi Oshero J, Kovalova-Muller A, Veigel Merino EA, Sauerbier S, Al-Jamali J, et al. Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw: technical report and follow up of 21 patients. J Craniomaxillofac Surg. 2012;40:719–25.View ArticlePubMedGoogle Scholar
- Connor SE, Chavda SV, Pahor AL. Computed tomography evidence of dental restoration as aetiological factor for maxillary sinusitis. J Laryngol Otol. 2000;114:510–3.View ArticlePubMedGoogle Scholar
- Fedele S, Porter SR, D'Aiuto F, Aljohani S, Vescovi P, Manfredi M, et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med. 2010;123:1060–4.View ArticlePubMedGoogle Scholar
- Kharazmi M, Hallberg P, Persson U, Warfvinge G. Bisphosphonate-associated osteonecrosis of the auditory canal. Br J Oral Maxillofac Surg. 2013;51:e285–7.View ArticlePubMedGoogle Scholar
- Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone. 2008;42:848–60.View ArticlePubMedGoogle Scholar
- Reid IR. Osteonecrosis of the jaw: who gets it, and why? Bone. 2009;44:4–10.View ArticlePubMedGoogle Scholar
- Ravosa MJ, Ning J, Liu Y, Stack MS. Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts. Arch Oral Biol. 2011;56:491–8.View ArticlePubMedGoogle Scholar
- Sun X, Wang D, Yu H, Hu L. Serial cytokine levels during wound healing in rabbit maxillary sinus mucosa. Acta Otolaryngol. 2010;130:607–13.View ArticlePubMedGoogle Scholar
- Wehrhan F, Stockmann P, Nkenke E, Schlegel KA, Guentsch A, Wehrhan T, et al. Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112:216–21.View ArticlePubMedGoogle Scholar
- Markose G, Mackenzie FR, Currie WJ, Hislop WS. Bisphosphonate osteonecrosis: a protocol for surgical management. Br J Oral Maxillofac Surg. 2009;47:294–7.View ArticlePubMedGoogle Scholar
- Lemound J, Eckardt A, Kokemuller H, von See C, Voss PJ, Tavassol F, et al. Bisphosphonate-associated osteonecrosis of the mandible: reliable soft tissue reconstruction using a local myofascial flap. Clin Oral Investig. 2012;16:1143–52.View ArticlePubMedGoogle Scholar
- Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826–36.View ArticlePubMedGoogle Scholar
- Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44:857–69.View ArticlePubMedGoogle Scholar
- Patel S, Choyee S, Uyanne J, Nguyen AL, Lee P, Sedghizadeh PP, et al. Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. Oral Dis. 2012;18:625–32.View ArticlePubMedGoogle Scholar
- Sakkas N, Schoen R, Schmelzeisen R. Orbital abscess after extraction of a maxillary wisdom tooth. Br J Oral Maxillofac Surg. 2007;45:245–6.View ArticlePubMedGoogle Scholar